 Aminophenols
"Aminophenols" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Phenols substituted in any position by an amino group.
| Descriptor ID |
D000627
|
| MeSH Number(s) |
D02.092.146.100 D02.455.426.559.389.657.050
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Aminophenols".
Below are MeSH descriptors whose meaning is more specific than "Aminophenols".
This graph shows the total number of publications written about "Aminophenols" by people in this website by year, and whether "Aminophenols" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 1 | 0 | 1 | | 2014 | 1 | 0 | 1 | | 2015 | 3 | 0 | 3 | | 2016 | 2 | 1 | 3 | | 2017 | 6 | 0 | 6 | | 2018 | 8 | 2 | 10 | | 2019 | 5 | 2 | 7 | | 2020 | 5 | 1 | 6 | | 2021 | 5 | 7 | 12 | | 2022 | 1 | 16 | 17 | | 2023 | 1 | 11 | 12 | | 2024 | 8 | 4 | 12 | | 2025 | 15 | 6 | 21 | | 2026 | 8 | 4 | 12 |
To return to the timeline, click here.
Below are the most recent publications written about "Aminophenols" by people in Profiles.
-
Zemanick ET, Graeber SY, Castellani C, Cutting GR, Fajac I, Konstan MW, Linnemann RW, McKone EF, Metcalf A, Solomon GM, Taylor-Cousar JL, Mayer-Hamblett N, Mall MA. The role of sweat chloride in determining CFTR protein restoration in people with cystic fibrosis. Lancet Respir Med. 2026 Aug; 14(8):704-716.
-
Chalamalla AR, Baker E, Ryan KJ, Dowell A, Natt JR, Zemanick ET, Konstan MW, Mayer-Hamblett N, Acosta EP, Guimbellot JS. Impact of CFTR modulator concentrations on clinical response in cystic fibrosis. Eur Respir J. 2026 Jun; 67(6).
-
Muther EF, Gibson SL, Ford C, Duncan C, Riekert KA, Lyons E, Hoppe JE, Prickett M, Isenburg MV, Everhart RS. People with cystic fibrosis' experience of symptom burden while taking elexacaftor/tezacaftor/ivacaftor. Respir Med. 2026 Aug; 259:108908.
-
Downey DG, Houston C, Mayer-Hamblett N, Taylor-Cousar JL, Taggart CC. Contributors to the heterogeneity of response to CFTR modulators. Lancet Respir Med. 2026 Aug; 14(8):717-729.
-
Van Braeckel E, Braun AT, Simmonds NJ, Barry PJ, Davies JC, Egan ME, Lapey A, Mall MA, McKone EF, Peckham D, Proesmans M, Ramsey B, Santamaria SV, Smith D, Taylor-Cousar JL, Tullis E, De Wachter E, Withers N, Ahluwalia N, Conner S, Jennings M, Lou Y, Weinstock TG, Keating D. Effects of Elexacaftor/Tezacaftor/Ivacaftor on cough frequency, physical activity patterns, and sleep quality in adolescents and adults with cystic fibrosis. J Cyst Fibros. 2026 Jul; 25(4):682-688.
-
Metcalf A, Hoppe JE, Martiniano SL, Zaretsky MV, Zemanick ET, Sagel SD. In Utero CFTR Modulator Therapy in Fetuses With Cystic Fibrosis. Neoreviews. 2026 Mar 01; 27(3):e157-e169.
-
Green N, Vu P, Xie J, Schwarzenberg SJ, Freedman S, Narkewicz M, Pittman J, Ratjen F, Rosenfeld M, Pope C, Duong J, Hoffman L, Heltshe S, Lusman SS. Impact of elexacaftor/tezacaftor/ivacaftor on gastrointestinal outcomes, inflammation, exocrine pancreatic function and fat malabsorption: Report of PROMISE pediatric substudy. J Cyst Fibros. 2026 May; 25(3):489-494.
-
Sagel SD, Poore TS, Wagner BD, Xie J, Heltshe SL, Cross M, Bratcher PE, Taylor-Cousar JL, Wilson A, McBennett K, Morgan SJ, Singh PK, Nichols DP, Kelly A, Solomon GM. Long-term reductions in inflammation in people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor. Ann Am Thorac Soc. 2026 02 01; 23(2):241-251.
-
Abi-Aad SJ, Tsalatsanis A, Narkewicz M, Leung DH, Khalaf RT. The Impact of Elexacaftor-Tezacaftor-Ivacaftor on Biochemical Surrogates of Cystic Fibrosis Hepatobiliary Involvement: A Retrospective Cohort Study. Pediatr Pulmonol. 2026 Feb; 61(2):e71522.
-
Castellani C, Mondejar-Lopez P, Van Goor F, Quon BS, Alghisi F, Fabrizzi B, Ramsey B, Taylor-Cousar JL, McKone EF, Tullis E, Weinstock TG, Tan V, Ahluwalia N, Mahic M, Liu L, Saayman S, Altshuler D, Waltz D, Mall MA, Fajac I. Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis and rare CFTR variants: in vitro translation to a phase 3, double-blind, randomized, placebo-controlled trial, and real-world study. Am J Respir Crit Care Med. 2026 Feb 01; 212(2):327-337.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|